Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Acquisitions & Divestments: 2018-2024

Historic Change in Acquisitions & Divestments for Kiniksa Pharmaceuticals International (KNSA) over the last 7 years, with Dec 2024 value amounting to $239.9 million.

  • Kiniksa Pharmaceuticals International's Change in Acquisitions & Divestments rose 74.67% to $84.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $246.2 million, marking a year-over-year increase of 24.06%. This contributed to the annual value of $239.9 million for FY2024, which is 36.71% up from last year.
  • As of FY2024, Kiniksa Pharmaceuticals International's Change in Acquisitions & Divestments stood at $239.9 million, which was up 36.71% from $175.5 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's Change in Acquisitions & Divestments' 5-year high stood at $407.1 million during FY2020, with a 5-year trough of $127.8 million in FY2022.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Change in Acquisitions & Divestments averaged around $181.1 million, with its median value being $175.5 million (2023).
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Change in Acquisitions & Divestments plummeted by 58.28% in 2022, and later skyrocketed by 37.33% in 2023.
  • Kiniksa Pharmaceuticals International's Change in Acquisitions & Divestments (Yearly) stood at $407.1 million in 2020, then dropped by 24.75% to $306.3 million in 2021, then slumped by 58.28% to $127.8 million in 2022, then surged by 37.33% to $175.5 million in 2023, then spiked by 36.71% to $239.9 million in 2024.